Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 108 in Type 2 Diabetes Mellitus
NCT00661921Phase 2Withdrawn
- Sponsor
- Amgen
- Start
- Jun 2008
- Primary completion
- Jun 2009
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of AMG 108 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Amgen. Primary endpoint: Change from baseline in HbA1c at 14 weeks. Planned start Jun 2008; status: withdrawn.
02
Drugs
AMG 108
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00661921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661921.